Non-invasive respiratory support for COVID-19-related acute respiratory failure

João Carlos Winck1, Joaquim Moreira2

1Department of Medicine, Faculty of Medicine-Porto University, Porto 4200-319, Portugal; 2Unidade Local de Saúde do Alto Minho, Viana do Castelo, Portugal.

The European Respiratory Society/American Thoracic Society clinical practice guidelines, which are only recommendatory, suggest utilization of non-invasive respiratory support therapies (NRST) as a preventive strategy for avoiding intubation in hypoxemic acute respiratory failure (ARF).[1] Theoretical concerns against the use of NRST are essentially related to safety reasons for the risk of the virus spreading among healthcare workers (HCW) and for the risk of delaying intubation in case of failure.

Recent experimental studies suggest that NRST are not "generating" bio-aerosols but more "dispersing" bio-aerosols farther away from the patient.[2] Moreover, it has been recently suggested that early invasive mechanical ventilation (IMV) was associated with an increased risk of day-60 mortality.[3]

NRST include continuous positive airway pressure (CPAP), bi-level positive-pressure ventilation (BLPPV), and high-flow nasal cannula oxygen (HFNCO), used in acute hypoxemic respiratory failure (AHRF) of different causes with different rates of success. HFNCO is beyond the scope of this article; however, it can be used sequentially or combined as an integrative NRST algorithm.[4] In this article, we review the experience so far on the use of CPAP and BLPPV and discuss the indications that can be used to ascertain the ideal time to start and the ideal settings.

CPAP and BLPPV Experience in Coronavirus Disease 2019 (COVID-19)

Literature review of NRST in COVID-19-related ARF identifies 24 publications including 2159 patients.[5-29] The average infection rate in HCW was 5%, less than the 12% reported in New York City among the staff not necessarily working with NRST.[10] Only two studies were performed in negative pressure rooms[11,27] and the series with the highest HCW infection rates[24] took place in Bergamo Emergency Department, in the high-stroke northern Italian town, during the first wave in Europe.

Only five series reported using advanced non-invasive ventilators,[7,11,13,15] while in four portable home ventilators were used[6,11,14,15] and in one intensive care unit ventilators.[6] The only important outcome reported in all papers was the success rate in avoiding endotracheal intubation, achieved on average in 53% and 59% of patients with, respectively, CPAP and BLPPV.

Employed protocols, methodology, and data collected in the published studies were extremely heterogeneous. Considering the 15 studies using CPAP, three did not disclose the mean pressures applied.[14,23,28] Mean CPAP pressures ranged from 10 cmH2O[10,22,26] to 15 cmH2O.[24] From the eight studies reporting BLPPV usage,[5,7,9,13,15,20,27] only two[7,27] reported mean pressure support and positive end-expiratory pressure (PEEP), respectively, 17.3/9.5 cmH2O and 12/6 cmH2O. In three, the indication to start BLPPV was the failure of HFNCO[5,20,27] and the rest was due to availability,[7] hypercapnia,[13,15] acidosis,[24] or CPAP failure.[13] All the five series applying facemask CPAP[8,6,11,15,28] used viral filters in the expiratory port of the circuit.

Helmet CPAP

With helmet CPAP, the advantage of less leakage conferred by the helmet may allow for more effective delivery of higher levels of positive end-expiratory pressure, potentially increasing alveolar recruitment and decreasing respiratory effort.[31] Helmet CPAP—mainly using a flow...
Non-invasive Positive Pressure Ventilation (NIPPV) and Risk of Self-Induced Lung Injury (SILI)

NIPPV in ARF has been implicated in the risk of SILI. An observational study, including 62 patients (47 with non-COVID-19 [acute respiratory distress syndrome]) showed that generated tidal volume (a surrogate of the measurement of transpulmonary pressure) was a good predictor for NIV failure. So, to avoid SILI, a “protective-NIV,” with lower tidal volumes between 6 mL/kg and 8 mL/kg has been proposed in the three studies that analyzed tidal volume levels included in a recent meta-analysis, only one showed a trend toward higher expiratory tidal volume in failure patients. None of the COVID-19 studies applying NRST refers to this topic.

CPAP or BLPPV in COVID-19: When to Start, When to Stop, and When to Wean

To decide when to start CPAP, there are three criteria: (1) If partial pressure of oxygen (PaO2): fraction of inspired oxygen (FiO2) ratios < 200 mmHg or PaO2 < 60 mmHg or respiratory rate (RR) > 30 breaths/min (while on oxygen or HFNCO). (2) If PaO2:FiO2 ratio is < 300 mmHg or oxygen saturation (SpO2) < 93% on O2 ≥ 5 L/min and the patient has body mass index > 30 kg/m² (optional). When starting CPAP, improvement in PaO2:FiO2 in 1 h should be analyzed. If improvement is ≥ 15% or ≥ 30%, consider the existence of lung recruitability. (3) When choosing CPAP with helmet or oro-nasal mask, start with 10 cmH2O (do not exceed 12–13 cmH2O to avoid barotrauma, SILI, or negative hemodynamic impact) to achieve SpO2 > 93% or PaO2 ≥ 60 mmHg.

Patients on helmet CPAP who do not show signs of respiratory distress (e.g., RR < 25 breaths/min) and maintain a SpO2 > 94% with a FiO2 < 50% and a PEEP ≤ 5 cmH2O could undergo a weaning trial. Patients who maintain a PaO2:FiO2 ratio > 250 mmHg on Venturi mask with a FiO2 < 40% for at least 24 h are considered successfully weaned from helmet CPAP.

It is suggested to reduce helmet CPAP level to the minimum possible (5–6 cmH2O), maintaining a FiO2 not higher than 50%. If de-recruitment is absent and the PaO2:FiO2 ratio is stable when compared with higher PEEP levels, the patient is ready to undergo a CPAP weaning trial. A weaning trial should be attempted every day to avoid a delay in CPAP removal.

The use of BLPPV as a first-line intervention should preferably be restricted to patients with COVID-19 who have hypercapnia (partial pressure of carbon dioxide [PaCO2] > 45 mmHg), due to chronic obstructive pulmonary disease, cardiogenic pulmonary edema, or morbid obesity/obstructive sleep apnea. For patients with hypoxemic respiratory failure not responsive to conventional oxygen therapy, HFNCO should be preferred.

To start BLPPV, there are three criteria: (1) PaO2:FiO2 ratios < 100 mmHg and RR ≥ 30 breaths/min and/or respiratory distress under CPAP. (2) Suggested parameters: PEEP 12 to 16 cmH2O and pressure support set with the aim of a tidal volume between 4 and 6 mL/kg and FiO2 set to a target of SpO2 90% to 95%. (3) In patients with hypercapnic respiratory failure (PaCO2 > 45 mmHg), in the history of medicine, we have never had such a high influx of patients with similar presentations ready to be included in prospective studies. Even if NRST have been demonstrated to be effective tools in preventing IMV in COVID-19 ARF, further studies designed to address important neglected issues are needed to better tailor each treatment for each individual case performed by each individual team. Nosocomial infection preventive and control measures during non-invasive positive pressure ventilation should be carefully implemented.

Conflicts of interest

None.

References

1. Rochwerg B, Brochard L, Elliott MW, Hess D, Hill NS, Nava S, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur Respir J 2017;50:1602426. doi: 10.1183/13993003.02426-2016.
2. Dhand R, Lu J. Coughs and sneezes: their role in transmission of respiratory viral infections, including SARS-CoV-2. Am J Respir Crit Care Med 2020;202:651–659. doi: 10.1164/rcrm.2020-0613PP.
3. Dupuis C, Bouadma L, de Montmollin E, Goldgran-Toledano D, Schwebel C, Reignier J, et al. Association between early invasive mechanical ventilation and day-60 mortality in acute hypoxemic respiratory failure related to coronavirus disease-2019 pneumonia. Crit Care 2021;3:e0329. doi: 10.1097/CCE.0000000000000329.
4. Winck JC, Scala R. Non-invasive respiratory support paths in hospitalized patients with COVID-19: proposal of an algorithm. Pulmonology 2021;30:312. doi: 10.1016/j.pulmoe.2020.12.005.
5. Vianello A, Arcaro G, Molena B, Turato C, Sutkhia A, Guarneri G, et al. High-flow nasal cannula oxygen therapy to treat patients with hypoxemic acute respiratory failure consequent to SARS-CoV-2 infection. Thorax 2020;75:998–1000. doi: 10.1136/thoraxjnl-2020-214993.
6. Oranger M, Gonzalez-Bermejo J, Dacosta-Noble P, Llontop C, Guerder A, Trosin-Desert V, et al. Continuous positive airway pressure to avoid intubation in SARS-CoV-2 pneumonia: a two-period retrospective case-control study. Eur Respir J 2020;56:2001692. doi: 10.1183/13993003.01692-2020.
7. Franco C, Fasciolongo N, Tonelli R, Dongilli R, Vianello A, Pisani L, et al. Feasibility and clinical impact of out-of-ICU noninvasive respiratory support in patients with COVID-19-related pneumonia. Eur Respir J 2020;56:2002130. doi: 10.1183/13993003.02130-2020.
8. Alvise S, Riller Q, Aboab J, Dlworth K, Billy PA, Lombardi Y, et al. Continuous positive airway pressure (CPAP) face-mask ventilation is an easy and cheap option to manage a massive influx of patients presenting acute respiratory failure during the SARS-CoV-2 outbreak: a retrospective cohort study. PLoS One 2020;15:e0240645. doi: 10.1371/journal.pone.0240645.
9. Ma X, Yin F, Zhang J, Peng H, Guan H, Gong P. Risk factors associated with failure of high-flow nasal cannula oxygen therapy in patients with severe COVID-19 in Wuhan, China. Available from: https://assets.researchsquare.com/4be4-b6f2-32a6a8a5eb38.pdf. 2020. [Last accessed on January 2, 2021]
11. Nightingale R, Nwosu N, Kutubudin F, Fletcher T, Lewis J, Frost F, et al. Is continuous positive airway pressure (CPAP) a new standard of care for type 1 respiratory failure in COVID-19 patients? A retrospective observational study of a dedicated COVID-19 CPAP service. BMJ Open Respir Res 2020;7:e000639. doi: 10.1136/bmjresp-2020-000639.

12. Goultou TG, Bellani G, Foti G, Frazer MJ, Fuchs BD, Cereda M. Early clinical experience in using helmet continuous positive airway pressure and high-flow nasal cannula in overweight and obese patients with acute hypoxic respiratory failure from coronavirus disease 2019. Crit Care Explo 2020;2:e0216. doi: 10.1097/CCE.0000000000000216.

13. Faraone A, Beltrame C, Crocian A, Carrai P, Lovicu E, Filetti S, et al. Effectiveness and safety of noninvasive positive pressure ventilation in the treatment of COVID-19-associated acute hypoxic respiratory failure: a single center, non-ICU setting experience. Intern Emerg Med 2021;16:1183–1190. doi: 10.1007/s11739-020-02562-2.

14. Noeman-Ahmed Y, Gokaraju S, Powrie DJ, Amran DA, El Sayed I, Rosdhy A. Predictors of CPAP outcome in hospitalized COVID-19 patients. Crit Care 2020;55:100358. doi: 10.1186/s13054-020-03363-9.

15. Burns GP, Lane ND, Tedd HM, Deutsch E, Douglas F, West SD, et al. Improved survival following ward-based non-invasive pressure support for severe hypoxia in a cohort of frail patients with COVID-19: retrospective analysis from a UK teaching hospital. BMJ Open Respir Res 2020;7:e000621. doi: 10.1136/bmjresp-2020-000621.

16. Alberti S, Radovanovic D, Billi F, Sotgiu G, Costanzo M, Piloacane T, et al. Helmet CPAP treatment in patients with COVID-19 pneumonia: a multicentre prospective observational study. Eur Respir J 2020;56:2001935. doi: 10.1183/13993003.01935-2020.

17. Patel M, Gangemi A, Marron R, Chowdhury J, Yousef I, Zheng M, et al. Multicentre retrospective analysis from a UK teaching hospital. BMJ Open Respir Res 2020;7:e000650. doi: 10.1136/bmjresp-2020-000650.

18. Guy T, Creac’hacée A, Ricordel C, Salé A, Arnaout B, Bicic JL, et al. High-flow nasal oxygen: a safe, efficient treatment for COVID-19 patients not in an ICU. Eur Respir J 2020;56:2001154. doi: 10.1183/13993003.01154-2020.

19. Calligaro GL, Lalla U, Audley G, Gina P, Miller MG, Mendelson M, et al. The utility of high-flow nasal oxygen for severe COVID-19 pneumonia in a resource-constrained setting: a multi-centre prospective observational study. EJCM 2020;28:100570. doi: 10.1186/eclinm.2020.100570.

20. Wang K, Zhao W, Li J, Shu W, Duan J. The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing, China. Am Intensive Care 2020;10:37. doi: 10.1186/s13163-020-00563-z.

21. Xia J, Zhang Y, Ni L, Chen L, Zhou G, Cao C, et al. High-flow nasal oxygen in coronavirus disease 2019 patients with acute hypoxemic respiratory failure: a multicenter, Retrospective Cohort Study. Crit Care Med 2020;48:e1079-e1086. doi: 10.1097/CCM.0000000000004588.

22. Brusasco C, Corradi F, Di Domenico A, Raggi F, Timossi G, Santori G, et al. Continuous positive airway pressure in Covid-19 patients with moderate to severe respiratory failure. Eur Respir J 2021;57:2002524. doi: 10.1183/13993003.02524-2020.

23. Di Domenico SL, Coen D, Bergamaschi M, Albertini V, Ghezzi L, Cazzaniga MM, et al. Clinical characteristics and respiratory support of 310 COVID-19 patients, diagnosed at the emergency room: a single-center retrospective study. Intern Emerg Med 2021;16:1051–1060. doi: 10.1007/s11739-020-02548-0.

24. Duca A, Menai J, Zanardi F, Preti C, Alesi A, Bella LD, et al. Severity of respiratory failure and outcome of patients needing a ventilatory support in the Emergency Department during Italian novel coronavirus SARS-CoV2 outbreak: preliminary data on the role of helmet CPAP and non-invasive positive pressure ventilation. EClinicalMedicine 2020;24:100419. doi: 10.1016/eclinm.2020.100419.

25. Demoule A, Veillard Baron A, Darmon M, Beurton A, Géri G, Voiriot G, et al. High-flow nasal cannula in critically ill patients with severe COVID-19. Am J Respir Crit Care Med 2020;202:1039–1042. doi: 10.1164/rcmcc.202003-20077LE.

26. Coppodaro A, Benini A, Fruscio R, Verga L, Mazzola P, Belleri G, et al. Helmet CPAP to treat hypoxic pneumonia outside the ICU: an observational study during the COVID-19 outbreak. Crit Care Med 2021;25:80. doi: 10.1097/CM9.0000000000001832.